JOP. J Pancreas (Online) 2014 Mar 10;
15(2):128-131.
The Role
of Biliary Drainage in Patients with Pancreatic Adenocarcinoma
Highlights from the “2014 ASCO
Gastrointestinal Cancers Symposium”.
San Francisco, CA, USA. January 16-18, 2014
Maria I Toki1,
Konstantinos N Syrigos1, Muhammad Wasif Saif2
1Oncology Unit,
Third Department
of Medicine, National and Kapodistrian University
of Athens, Medical School, Sotiria General Hospital. Athens, Greece. 2Department of Medicine and Cancer Center, Tufts Medical Center. Boston, MA, USA
Summary
Pancreatic cancer
is one of the leading causes of cancer deaths worldwide and constitutes a major public health problem. One of the most common symptoms associated
with pancreatic
adenocarcinoma is
jaundice, caused
by the obstruction of common bile duct. Endobiliary stenting is used to relief these patients either preoperatively or merely for palliation and plastic or metal stents are usually endoscopically or percutaneously placed.
Two interesting
studies were presented at the 2014 ASCO Gastrointestinal Cancers
Symposium. Strom et al. sought to investigate the effect of preoperative biliary drainage on recurrence and survival and they concluded that percutaneous biliary
decompression was
an independent
predictor of worse overall survival and was associated with non-significant
increase in hepatic recurrence (Abstract #314). Montero et al. presented the results of their study regarding the cost-effectiveness of
metal stents in patients with inoperable pancreatic cancer and they concluded that placement of metal biliary stents is cost saving, improves overall survival and quality-adjusted survival
compared with
plastic stents
(Abstract #260).
Both studies concluded to useful results that along with the existing literature
and formulated
guidelines may
help the provision of more effective, higher quality management of these patients.
Introduction
Pancreatic cancer is the
13th most common type of cancer worldwide and the fourth
leading cause
of cancer-related
mortality in the United States [1].
During the year 2013, it is estimated that approximately 45,220 people were
diagnosed with pancreatic adenocarcinoma and 38,460 died from it [2]. Despite
the ongoing advances in diagnosis and treatment of pancreatic cancer, the
overall five-year survival rate from all stages of the disease remains as low
as 5% [3]. With the majority of patients presenting with inoperable, locally
advanced tumors or metastatic disease [2], most of them will appear
with symptoms related to the disease. As most tumors are found in the head of the pancreas, jaundice due to bile duct obstruction is a common presenting symptom.
It is estimated that 80% of patients with adenocarcinoma of the head
of the pancreas, will suffer from obstructive jaundice at some time during the course
of their disease and may require biliary drainage either preoperatively or merely
for palliation.
What
We Knew Before the 2014 ASCO Gastrointestinal Cancers Symposium
Preoperative biliary drainage,
in patients with potentially resectable lesions, is a safe intervention to relieve
disease related symptoms such as pruritus and cholangitis. It may improve liver
function and can also be applied to maintain the patency of the common bile duct
during neoadjuvant therapy or in patients whose surgical intervention is expected
to be delayed. However, the role of preoperative biliary drainage performed using
either percutaneous transhepatic or endoscopic techniques, remains controversial
in terms of morbidity and mortality.
Apart from the patients whom
their disease stage is amenable to surgical intervention, a large proportion of
patients will present with locally advanced, unresectable and metastatic disease.
The majority of these patients will present with obstructive jaundice which, if
left untreated, will result in malabsorption, cholestasis, progressive hepatic failure
and early death. Therefore, alleviation of jaundice represents a critical component
of palliation. In these patients palliation is best provided by endoscopic biliary
stenting. Although in most cases metal stents are preferred over plastic ones, the
debate continues in terms of efficacy and cost effectiveness.
What
We Have Learned at the 2014 ASCO Gastrointestinal Cancers Symposium
Overall Survival with Preoperative
Biliary Drainage in Patients with Resectable Pancreatic Cancer (Abstract #314)
[4]
The role of preoperative
biliary drainage remains a matter of controversy. This topic was the subject of
an abstract presented by Strom et al. [4]. They conducted a study based on
their institutional tumor registry to evaluate its role in recurrence and survival
in patients with resectable pancreatic cancer. The study population included a total
of 202 patients who were either operated without preoperative biliary drainage or
subjected to drainage endoscopically (via ERCP) or percutaneously (via percutaneous
transhepatic biliary drainage).
The
three aforementioned groups differed significantly in the mean pathologic tumor
size (P=0.005), pathologic T3/4 (P=0.01) and pathologic N1 (P=0.007) status. In
their results (Table 1), the authors showed that patients who underwent percutaneous
transhepatic biliary drainage exhibited a non-significant increased rate of hepatic
recurrences compared to the other groups of patients (P=0.20) and a worse median
and 3-year survival compared to the patients that underwent ERCP or no biliary decompression
at all (P=0.02). Percutaneous biliary drainage was also found to be an independent
predictor of worse overall survival (P=0.005) using multivariate analysis. These
results may suggest that patients that require preoperative percutaneous
transhepatic biliary drainage may benefit from neoadjuvant therapy prior to the
surgical intervention.
Table
1. The results of the study of Strom et al. [4] (Abstract
#314).
|
|
Percutaneous
transhepatic biliary drainage
|
Endoscopic
retrograde cholangiopancreatography
|
No biliary
drainage
|
P value
|
Preoperative
biliary procedures:
- None or 1
- More than> 1
|
27 (81.8%)
6 (18.2%)
|
85 (86.7%)
13 (13.3%)
|
114 (100%)
0
|
<0.001
|
Time
from diagnosis to surgery (days):
- Median (range)
- Mean±SD
|
29 (1-67)
30±15
|
16 (0-84)
19±17
|
13 (0-70)
17±18
|
<0.001
0.001
|
Pathologic
tumor size (cm):
- Median (range)
- Mean±SD
|
2.5 (1.2-5.5)
3.1±1.1
|
2.9 (0.1-12.0)
3.0±1.5
|
3.1 (0.1-4.7)
3.6±1.9
|
0.04
0.02
|
Tumor
T stage:
- 1
- 2
- 3
- 4
|
1 (3.0%)
5 (15.2%)
27 (81.8%)
0
|
6 (6.1%)
7 (7.1%)
83 (84.7%)
2 (2.0%)
|
9 (7.9%)
29 (25.4%)
73 (64%)
3 (2.6%)
|
0.02
|
Nodes
removed; median (range)
|
16
(0-29)
|
12
(1-45)
|
11
(0-49)
|
0.03
|
Tumor N stage:
- 0
- 1
|
6 (18.2%)
27 (81.8%)
|
34 (34.7%)
64 (65.3%)
|
56 (49.1%)
58 (50.9%)
|
0.003
|
Survival:
- Median
- 3-year
- 5 year
|
17.5 months
18%
3%
|
22.8 months
34%
23.7%
|
26.3 months
41%
27.2%
|
-
|
SD: standard deviation
|
Cost-Effectiveness of Metal
Stents in Pancreatic Cancer (Abstract #260) [5]
Patients with pancreatic
adenocarcinoma usually present with locally advanced, unresectable or metastatic
disease [2]. In this group of patients, biliary decompression may be required for
palliation. Montero et al. presented the results of their study regarding
the cost-effectiveness of metal stents in pancreatic cancer [5]. In the study were
included patients with locally advanced pancreatic cancer, who underwent ERCP with
metal or plastic stent placement. The results suggest that patients with metal stents
had lower costs and greater overall and quality-adjusted survival. Specifically,
the investigators found that metal stent implementation resulted in approximately
$1,500 saved per patient over a lifetime and fewer stents placed (mean number: 1.4
vs. 2.8). Moreover, metal stenting improved the overall survival by 0.07
months and the quality-adjusted survival by 0.10 months.
Discussion
Preoperative biliary drainage
in patients with potentially resectable pancreatic cancer is mainly indicated for
the alleviation of disease-related symptoms like pruritus and cholangitis. Although
controversial, several studies have suggested that pancreatic surgery is associated
with higher perioperative mortality when performed in the setting of hyperbilirubinemia
and impaired liver function [6] and thus preoperative biliary decompression may
be mandated. Nonetheless, a number of prospective and retrospective studies
have failed to demonstrate decreased mortality in patients with preoperative
biliary drainage [7, 8, 9, 10, 11, 12, 13]. A study by Povoski et al. showed
that the risk of infectious complications, intra-abdominal abscess and death were
increased with biliary drainage [14]. In another multicenter randomized trial,
it was shown that preoperative biliary drainage resulted in 2-fold increased
rate of serious complications compared with the patients that underwent surgery
alone. However, no significant differences were found in surgery associated
complications, length of hospital stay or mortality [15].
In the 2014 ASCO Gastrointestinal
Cancer Symposium, Strom et al. presented the results of their retrospective
study regarding the role of preoperative biliary drainage in patients with resectable
pancreatic cancer [4]. Their findings are in line with the existing literature.
They came to the conclusion that preoperative biliary decompression not only has
no favorable effect on survival, but percutaneous transhepatic biliary drainage
was found to be an independent prognostic factor associated with worse overall survival.
However, there are some concerns regarding the study. First of all, the data derive
from a retrospective analysis. Moreover, there are significant key differences between
the study groups in terms of pathologic features with percutaneous transhepatic
biliary drainage group patients presenting the most aggressive ones. Nonetheless,
the authors acknowledge that the observed results regarding percutaneous
transhepatic biliary drainage are likely attributed to multiple factors including
more advanced disease stage, delayed surgical intervention, increased number of
preoperative biliary procedures and increased rate of hepatic metastases, possibly
from tumor seeding.
Therefore, it seems reasonable
- as stated in the National Comprehensive Cancer Network (NCCN) guidelines - to
implement preoperative biliary decompression only in patients who present with jaundice
and symptoms of cholangitis or fever, severe pruritus or in whom operation is expected
to be significantly delayed (more than 1 week). Finally, although not the topic
of this study, it should be mentioned that biliary drainage is necessary for patients
with jaundice undergoing neoadjuvant therapy prior to surgery.
Biliary
drainage, apart from its role in the preoperative period, also constitutes an important
component of our armamentarium for the palliative management of the large proportion
of patients with inoperable disease. Endoscopic approaches for
palliation of pancreatic adenocarcinoma are rapidly expanding. However, it is still
not clear which type of stent should be used.
To
date, many trials have compared metal and plastic stents in patients with biliary
obstruction due to pancreatic adenocarcinoma. Plastic stents become more frequently
occluded, usually within 3 months of insertion resulting in recurrent cholangitis.
On the contrary, metal stents are wider in diameter and thus less likely to become
occluded. The results of a randomized controlled trial, that compared the patency
of plastic and covered self-expanded metal stents, exhibited significantly prolonged
patency for metal stents [16]. This study concluded that metal stents could be
recommended in inoperable patients with malignant common bile duct strictures
that survive a median of 4.5 months. Less costly plastic stents are preferable
in the one third of patients who have distant metastases, although the cost in
both cases was equal [16]. Similar were the results of a meta-analysis,
published in the Cochrane database. The meta-analysis compared metal and
plastic stents in patients with biliary obstruction due to pancreatic cancer
and showed lower risk of recurrent biliary obstruction when metal stents were
used [17].
Some
institutions use plastic stents in patients with locally advanced or metastatic
disease and short life expectances, because of the lack of concern about long
term patency. Many studies support that, since biliary self-expanding metal
stents are significantly more expensive than plastic stents, their use should
be reserved for patients whose estimated survival is greater than 3 to 4 months
[18] and/or those patients without liver metastases [19]. However, the initial higher
cost of metal stents might be balanced by a decreased need for repeat intervention
due to lower occlusion.
The
issue of cost/effectiveness of metal stents was the topic of an abstract presented
in the 2014 ASCO Gastrointestinal Cancer Symposium by Montero et al. [5].
The authors found that placement of metal biliary stents in jaundiced patients with
stage III pancreatic adenocarcinoma resulted in a modest decrease in cost compared
to plastic stents. This finding could, in part, be attributed to fewer stents being
placed. Moreover, patients with metal stents were estimated to have 0.32 months
of higher quality-adjusted life years. However, there are some specific limitations
of the study, acknowledged by the authors themselves. Namely, the selection bias
resulting from the used references for clinical inputs cannot be excluded, there
is uncertainty around many of the parameters estimates, the cost inputs were based
exclusively on United States data and, finally, they used utility weights for similar
but not identical health conditions. Nonetheless, the study offers valuable information,
useful for the appreciation of cost effectiveness of metal stents.
All the aforementioned data have been the basis for the formulation
of guidelines regarding biliary drainage. According to the American Society for
Gastrointestinal Endoscopy (ASGE) guidelines, endoscopic stent placement is recommended
for the alleviation of obstructive jaundice in patients with unresectable or metastatic
disease. Specifically, they propose plastic stents for patients with estimated life
expectancy of less than 6 months and metal stents for those with life expectancy
of more than 6 months [20]. More recently, the NCCN guidelines recommended the use
of permanent self-expanding metal stents as the preferred method.
Key words Palliative Care;
Pancreatic Neoplasms; Stents
Abbreviations ERCP: endoscopic
retrograde cholangiopancreatography; NCCN: National Comprehensive Cancer
Network
Conflicts of interest
Authors report no conflict of interest
Correspondence
Maria
I Toki
Oncology Unit
Third Department of Medicine
National and Kapodistrian University of Athens, Medical School
Sotiria General Hospital
152 Mesogeion Ave
11527, Athens
Greece
Phone: +30-210.770.0220
Fax: +30-210.778.1035
E-mail: maria_toki@yahoo.com
References
1. Parkin DM, Bray
F, Ferlay J, et al. Global cancer statistics, 2002. CA: a cancer journal for
clinicians 2005;55(2):74-108.
2. Siegel R,
Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for
clinicians 2013;63(1):11-30.
3. Ries L, Melbert
D, Krapcho M, et al. SEER cancer statistics review 1975–2004; based on November
2006 SEER data submission. http://seercancergov/csr/1975_2004/ Bethesda, MD:
National Cancer Institute, 2007 2007.
4. Strom T, Hoffe S,
Vignesh S, et al. Overall survival with preoperative biliary drainage in
patients with resectable pancreatic cancer. J Clin Oncol 2014;32(Supp. 3):abstr
314.
5. Montero A,
Meckley L, Anene A, et al. Cost-effectiveness of metal stents in pancreatic
cancer. J Clin Oncol 2014;32(Suppl 3):abstr 260.
6. Bottger TC,
Junginger T. Factors influencing morbidity and mortality after
pancreaticoduodenectomy: critical analysis of 221 resections. World journal of
surgery 1999;23(2):164-171; discussion 171-162.
7. Gundry SR,
Strodel WE, Knol JA, et al. Efficacy of preoperative biliary tract
decompression in patients with obstructive jaundice. Archives of surgery
1984;119(6):703-708.
8. Hatfield AR,
Tobias R, Terblanche J, et al. Preoperative external biliary drainage in
obstructive jaundice. A prospective controlled clinical trial. Lancet
1982;2(8304):896-899.
9. Heslin MJ, Brooks
AD, Hochwald SN, et al. A preoperative biliary stent is associated with
increased complications after pancreatoduodenectomy. Archives of surgery
1998;133(2):149-154.
10. Lai EC, Mok FP,
Fan ST, et al. Preoperative endoscopic drainage for malignant obstructive
jaundice. The British journal of surgery 1994;81(8):1195-1198.
11. McPherson GA,
Benjamin IS, Hodgson HJ, et al. Pre-operative percutaneous transhepatic biliary
drainage: the results of a controlled trial. The British journal of surgery
1984;71(5):371-375.
12. Pitt HA, Gomes
AS, Lois JF, et al. Does preoperative percutaneous biliary drainage reduce
operative risk or increase hospital cost? Annals of surgery
1985;201(5):545-553.
13. Thomas JH,
Connor CS, Pierce GE, et al. Effect of biliary decompression on morbidity and
mortality of pancreatoduodenectomy. American journal of surgery
1984;148(6):727-731.
14. Povoski SP,
Karpeh MS, Jr., Conlon KC, et al. Association of preoperative biliary drainage
with postoperative outcome following pancreaticoduodenectomy. Annals of surgery
1999;230(2):131-142.
15. van der Gaag NA,
Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the
head of the pancreas. The New England journal of medicine 2010;362(2):129-137.
16. Soderlund C,
Linder S. Covered metal versus plastic stents for malignant common bile duct
stenosis: a prospective, randomized, controlled trial. Gastrointestinal
endoscopy 2006;63(7):986-995.
17. Moss AC, Morris
E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic
carcinoma. The Cochrane database of systematic reviews 2006(2):CD004200.
18. Yeoh KG,
Zimmerman MJ, Cunningham JT, et al. Comparative costs of metal versus plastic
biliary stent strategies for malignant obstructive jaundice by decision
analysis. Gastrointestinal endoscopy 1999;49(4 Pt 1):466-471.
19. Kaassis M, Boyer
J, Dumas R, et al. Plastic or metal stents for malignant stricture of the
common bile duct? Results of a randomized prospective study. Gastrointestinal
endoscopy 2003;57(2):178-182.
20. Baron TH,
Mallery JS, Hirota WK, et al. The role of endoscopy in the evaluation and
treatment of patients with pancreaticobiliary malignancy. Gastrointestinal
endoscopy 2003;58(5):643-649.